Truly, I understand everyone's desire to see this happen quickly, but safety and adherence is more important. To temper some of your points...
(1). No second patient has been dosed in the HCV study.
Regardless of the delay, the last PR said it would be AT LEAST 28 days, not only 28 days.
(2). No additional sites have opened as French promised.
according to clinical trials dot gov, both sites are now open for recruiting.
(3). I have not been following these trials as much, so I can't honestly respond to those ATM.
All that aside, there has been NO negative news. Nobody has died or been seriously injured in all the areas that ddRNAi has been used up to this point. Calimmune is still advancing their HIV program, and second dosing should be soon. There is nothing that I can see to worry about except for a temporary dip in share price while we wait. All long Benitec holders know this trial needs to be followed precisely, since benitec is breaking new ground and don't want to screw it up. It's just a waiting game right now. The share price will reflect their true worth when robust data on efficacy comes through. For now, we want to do no harm.
- Forums
- ASX - By Stock
- BLT
- Sigma-Aldrich taken over by Merck for
Sigma-Aldrich taken over by Merck for, page-9
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BLT (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
JBY
JAMES BAY MINERALS LIMITED
Andrew Dornan, Executive Director
Andrew Dornan
Executive Director
Previous Video
Next Video
SPONSORED BY The Market Online